Akums Q4 net profit ₹813.42 million vs ₹1,496.06 million; ₹3 dividend recommended
Akums Drugs & Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated profit for the quarter ended 31 March 2026 was ₹813.42 million against ₹1,496.06 million a year earlier; revenue from operations was ₹11,578.68 million vs ₹10,555.47 million.
- Board recommended a final dividend of ₹1 and a special dividend of ₹2 per share for FY 2026, record date July 3, 2026, subject to shareholder approval at the AGM on July 10, 2026.
- Mahajan & Aibara LLP appointed internal auditors for FY 2026-27; V Jagannathan appointed and Arvind Srivastava ceased as Senior Management Personnel (President - HR) from May 14, 2026.
Why it's rated major development: the year-on-year change is 46% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Change in Management
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Akums Drugs & Pharmaceuticals
- Acquisition / mergerMajor developmentAkums Drugs reports Q2 FY27 results and acquires Oriflame India's manufacturing business
- Financial resultsMajor developmentAkums Drugs board approves unaudited results for quarter ended 30 June 2026
- Financial resultsMajor developmentAkums Drugs approves June 2026 quarter results; consolidated tax demand of 560.8 million raised
- Financial resultsMajor development· Adverse for the businessAkums Drugs approves audited FY26 results, recommends dividends, changes senior management
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Drugs approves FY 2026 results, appoints auditors, and announces dividends
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.